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Abstract
Background: Replacement of proinsulin C-peptide in type 1 diabetes ameliorates nerve and kidney dysfunction, conditions
which are associated with a decrease in Na,K-ATPase activity. We determined the molecular mechanism by which long term
exposure to C-peptide stimulates Na,K-ATPase expression and activity in primary human renal tubular cells (HRTC) in control
and hyperglycemic conditions.
Methodology/Principal Findings: HRTC were cultured from the outer cortex obtained from patients undergoing elective
nephrectomy. Ouabain-sensitive rubidium (
86Rb
+) uptake and Na,K-ATPase activity were determined. Abundance of Na,K-
ATPase was determined by Western blotting in intact cells or isolated basolateral membranes (BLM). DNA binding activity
was determined by electrical mobility shift assay (EMSA). Culturing of HRTCs for 5 days with 1 nM, but not 10 nM of human
C-peptide leads to increase in Na,K-ATPase a1-subunit protein expression, accompanied with increase in
86Rb
+ uptake, both
in normal- and hyperglycemic conditions. Na,K-ATPase a1-subunit expression and Na,K-ATPase activity were reduced in BLM
isolated from cells cultured in presence of high glucose. Exposure to1 nM, but not 10 nM of C-peptide increased PKCe
phosphorylation as well as phosphorylation and abundance of nuclear ERK1/2 regardless of glucose concentration.
Exposure to 1 nM of C-peptide increased DNA binding activity of transcription factor ZEB (AREB6), concomitant with Na,K-
ATPase a1-subunit mRNA expression. Effects of 1 nM C-peptide on Na,K-ATPase a1-subunit expression and/or ZEB DNA
binding activity in HRTC were abolished by incubation with PKC or MEK1/2 inhibitors and ZEB siRNA silencing.
Conclusions/Significance: Despite activation of ERK1/2 and PKC by hyperglycemia, a distinct pool of PKCs and ERK1/2 is
involved in regulation of Na,K-ATPase expression and activity by C-peptide. Most likely C-peptide stimulates sodium pump
expression via activation of ZEB, a transcription factor that has not been previously implicated in C-peptide-mediated
signaling. Importantly, only physiological concentrations of C-peptide elicit this effect.
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Introduction
C-peptide, the connecting segment of proinsulin, is secreted by
pancreatic b-cells into the circulation together with insulin in
equimolar quantities. One role of C-peptide is to participate in the
proper folding of proinsulin by facilitating correct disulfide bond
formation between the A- and B-chain of insulin. A series of
studies during the past decade have presented new aspects of C-
peptide physiology. C-peptide administration corrects glomerular
hyperfiltration characteristic of the early stages of diabetic
nephropathy, reduces urinary excretion of albumin and prevents
the development of glomerular hypertrophy in type 1 diabetes [1].
C-peptide infusion prevents experimentally induced type 1
diabetes-dependent decrease of renal Na,K-ATPase a1-subunit
in rats [2]. In patients with type 1 diabetes and in animal models of
the disease, administration of C-peptide in physiological concen-
trations results in improvements of diabetes-induced functional
and structural changes of peripheral nerves [3,4,5]. C-peptide in
replacement doses prevents diabetes-induced deficits in nerve fiber
regeneration [6], protects against glucose-induced apoptosis, and
stimulates cellular proliferation [7].
The molecular mechanisms by which C-peptide exerts its effects
are now beginning to emerge. C-peptide binds to membrane
binding site on a number of different cell types, thereby triggering
pertussis toxin sensitive, Ca
2+-dependent intracellular signaling
pathways, including protein kinase C (PKC) isoforms and the
mitogen-activated protein (MAP) kinase cascade [8,9]. C-peptide
may exert insulinomimetic effects via interaction with the insulin
signaling pathways at the level of the insulin receptor or
downstream of it [10]. C-peptide acutely stimulates Na,K-ATPase
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28294activity via PKC and MAP activation kinase activation in human
renal tubular cells [11,12]. Activation of the Na-pump is of
particular clinical interest, as it is reported to be deficient in type 1
diabetes in a number of tissues [2,13,14]. Given the central role of
Na,K-ATPase in the regulation of intracellular ion concentrations,
a reduction in Na,K-ATPase activity may contribute to decreased
nerve conduction velocity, retinal cell dysfunction, impaired
endothelial function and decreased microvascular blood flow,
kidney disorders and development of hyperkalemia [15,16,17].
The decreased Na,K-ATPase activity found in association with
diabetes mellitus and its complications can be restored to normal
by administration of C-peptide [2,3,18], although the mechanism
of this stimulation is not completely understood.
Na,K-ATPase is a ubiquitously expressed plasma membrane
cation pump, which is essential for maintenance of intracellular
and extracellular sodium and potassium concentrations, cell
volume, osmotic balance and electrochemical gradients [19].
The regulation of Na,K-ATPase can be achieved via multiple
mechanisms, including changes in intrinsic activity, subcellular
distribution and cellular abundance [20]. Apart from classical
regulation by steroid and thyroid hormones [20], the molecular
regulation of genes encoding Na,K-ATPase subunits under
physiological conditions where Na,K-ATPase expression is
altered, such as hypokalemia [21], starvation [22], or diabetes
[13], is largely unknown. The gene promoter of the Na,K-ATPase
a1-subunit predominantly expressed in the kidney contains
consensus sequences for several transcription factors [23].
Moreover, MAP kinases have been implicated in the regulation
of Na,K-ATPase expression. Activation of ERK1/2 signaling
pathway leads to an increase in synthesis of Na,K-ATPase subunits
[24]. Consequently, in this study we examined the molecular
mechanism by which long term exposure to physiological and
elevated concentration of C-peptide stimulates Na,K-ATPase
expression and activity in primary human renal tubular cells in
control and hyperglycemic conditions.
Results
Physiological concentrations of C-peptide stimulate Na,K-
ATPase protein expression and activity in HRTC in culture
Culturing of HRTCs with 1 nM, but not 10 nM, of human C-
peptide for 5 days leads to an increase in Na,K-ATPase a1-subunit
protein expression (Fig. 1A), accompanied with increase in Na,K-
ATPase ion transporting activity measured as
86Rb
+ uptake
(Fig. 1B), both in normal- and hyperglycemicconditions. Scrambled
C peptide has no effect on Na,K-ATPase expression and activity
(data not shown). Viability and morphology as assessed by light
microscopy of HRTC after incubation with the C-peptide were
similar to those for control cells. The Na,K-ATPase a1-subunit
abundance and Na,K-ATPase enzymatic activity were also
increased in basolateral membrane fractions isolated from HRTC
(Fig. 1C and D). While high glucose concentration does not affect
Na,K-ATPase a1-subunit expression and Na,K-ATPase activity
when determined in whole cells, Na,K-ATPase a1-subunit abun-
dance (Fig. 1C) and Na,K-ATPase enzymatic activity (Fig. 1D) were
specifically reduced in basolateral membrane fractions isolated from
cells cultured in presence of high glucose, suggesting that during
hyperglycemia Na,K-ATPase internalized from cell surface and
sequestered in an intracellular stores.
Effects of long term C-peptide exposure on PKC
activation
Acute stimulation by C peptide specifically activates PKC
isoforms d and e in HRTC [8]. Phospho-PKC isoform-specific
antibodies (pPKC a/b, d, e) were used to detect the effects of C-
peptide and high glucose concentrations on the phosphorylation as
an indication of activation of different PKC isoforms. Culturing of
HRTC in the presence of high glucose leads to an increase in
PKCa/b phosphorylation in the absence or in the presence of C-
peptide, regardless of C-peptide concentrations (Fig. 2A). PKCd
phosphorylation was slightly increased after exposure to 10 nM,
but not 1 nM of C-peptide (Fig. 2B). Exposure to 1 nM, but not
10 nM of C-peptide increased PKCe phosphorylation regardless
of glucose concentrations (Fig. 2C).
Physiological concentrations of C-peptide leads to ERK1/
2 phosphorylation and nuclear localization
The total ERK1 expression in HRTC cells was not affected by
exposure to C-peptide or hyperglycaemia. (Fig. 3A). However,
the ERK1 nuclear abundance was increased after exposure to
1 nM of but not 10 nM C-peptide (Fig. 3B). High glucose
concentrations did not alter the effect of 1 nM C-peptide.
Exposure to high glucose leads to an increase in phosphorylation
of total ERK1/2, independent of the presence of C-peptide
(Fig. 3C). At 5 mM glucose concentration both 1 nM and 10 nM
C-peptide significantly stimulates total ERK1/2 phosphoryla-
tion (Fig. 3C). The effect of C-peptide on total ERK1/2
phosphorylation was not additive to the effect of hyperglycemia.
However, only exposure to 1 nM of C-peptide increased nuclear
E R K 1 / 2p h o s p h o r y l a t i o nb o t hi nn o r m a l -a n dh y p e r g l y c e m i c
conditions (Fig. 3D), reflecting increased nuclear ERK abun-
dance (Fig. 3B).
Effects of long term C-peptide and glucose exposure on
ZEB DNA binding in HRTC
In parallel with the C-peptide-induced increase Na, K, ATPase
a1-subunit expression and ouabain-sensitive
86Rb
+ uptake, expo-
sure to 1 nM of C-peptide increased DNA binding activity of ZEB
(AREB6) (Fig. 4A), a transcription factor involved in regulation of
Na,K-ATPase a1-subunit expression [25]. In unstimulated cells
basal ZEB DNA binding activity was nearly undetectable. ZEB
DNA binding activity was only slightly increased by exposure to
10 nM C-peptide. The effect of C-peptide on ZEB DNA binding
was unaffected by glucose concentration. The specificity of C-
peptide induced ZEB DNA binding in HRTC was confirmed by
electrophoretic mobility supershift assay utilizing specific antibodies
against ZEB (Fig. 4B). The C-peptide-induced ZEB DNA binding
activity was concomitant with increased Na,K-ATPase a1-subunit
mRNA expression (Fig. 4C).
C-peptide-induced expression of the Na,K-ATPase in
HRTC is PKC- and ERK1/2 -dependent
Effects of 1 nM C-peptide on ERK1/2 phosphorylation, ZEB
DNA binding activity and Na,K-ATPase a1-subunit expression in
HRTC were abolished by overnight incubation with a PKC
inhibitor (1 mM GF109203X) or MEK1/2 inhibitor (10 mM
PD98059), suggesting involvement of conventional and novel
PKCs and ERK1/2 in regulation of C-peptide induced sodium
pump expression (Fig. 5A).
ZEB silencing in HRTC
Gene silencing of ZEB reduced protein abundance (Fig. 5B) by
60% (p,0.05), followed by a markedly reduced effect of 1 nM C-
peptide on increase in Na,K-ATPase a1-subunit expression.
Growth and gross morphology as assessed by light microscopy of
HRTC with depleted ZEB expression were similar to those in cells
transfected with siRNA against a scrambled sequence.
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In recent years much new information has been presented
indicating that C-peptide may be a bioactive endogenous hormone
in its own right. Specifically, several reports have indicated that C-
peptide elicits activation of Na,K-ATPase, an enzyme of crucial
importance for cellular sodium and potassium ion homeostasis and
membrane potential [2,3,12,26]. Previously we have reported an
acute stimulatory effect of the physiological concentrations of C-
peptide on the sodium pump activity in HRTC [12]. In the
present study we evaluated the long-term effect of C-peptide on
Na,K-ATPase under normo- and hyperglycemic conditions in
cells of human origin, and determined the molecular pathways of
C-peptide action. Our results indicate that physiological concen-
trations of C-peptide stimulate Na,K-ATPase expression in
HRTC by activation of a PKC- and MAP kinase-dependent
pathway. Importantly, a scrambled sequence of the amino acids
constituting human C-peptide was without effect on Na,K-ATPase
expression, activity and cell signaling events. The stimulatory effect
of C-peptide on sodium pump expression and activity overcomes
the hyperglycemia-induced sodium pump downregulation. These
findings are of particular interest since they are in agreement with
in vivo studies in BB/W rats showing improved Na,K-ATPase
levels in the sciatic nerve after exposure to physiological levels of
C-peptide [3]. One week C-peptide infusion prevents type 1
diabetes-induced decrease of renal Na,K-ATPase a1-subunit in
rats [2]. The observations also underscore the potential role of C-
peptide as a therapeutic modality in patients with type 1 diabetes
and its complications, particularly with regards to peripheral
neuropathy [27].
Figure 1. Effects of different C-peptide and glucose concentrations on Na,K-ATPase expression and activity in HRTC. Cells were
cultured and analyzed as described in ‘‘Materials and Methods’’. A. C-peptide at 1 nM concentration stimulates Na,K-ATPase protein expression. A
representative Western blot image is shown in the upper panel. GAPDH protein was used as a loading control. B. Ouabain-sensitive
86Rb
+ uptake in
intact HRTC. C. Na,K-ATPase a1-subunit abundance in basolateral membrane fractions isolated from HRTC. A representative Western blot image is
shown in the upper panel. GLUT2 protein was used as a loading control. D. Na,K-ATPase enzymatic activity in basolateral membrane fractions
isolated from HRTC. Results are means 6 SE for 6 independent experiments. * P,0.05 versus 5 mM glucose without C-peptide. { P,0.05 versus
5 mM glucose with 1 nM of C-peptide.
doi:10.1371/journal.pone.0028294.g001
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Na,K-ATPase functions in the diabetic state have been linked to
hyperglycemia via activation of PKC and a subsequent decrease in
Na,K-ATPase activity due to phosphorylation of the alpha-subunit
[28]. PKC activation elicits phosphorylation of the Na,K-ATPase
a1-subunit and promotes endocytosis of the sodium pump units
[29]. Indeed, in diabetic animal models, PKC activity is increased
in retina, glomeruli, aorta, skeletal muscle, and heart, concomitant
with decrease in Na,K-ATPase activity [30,31,32,33]. Inhibition
of PKCb prevents the hyperglycemia-induced decrease in Na,K-
ATPase activity in retina [15]. However, neither strict glycemic
control nor restoration of normal glycemia and PKC activity
[17,34] can completely restore Na,K-ATPase activity.
We found that in human renal tubular cells hyperglycemia
causes a decrease in Na,K-ATPase abundance and activity in
basolateral membrane in parallel with activation of conventional
PKCa and b. Conventional PKCs have been implicated in
regulation of endocytosis of the sodium pump [20,29]. However,
only stimulation with physiological concentrations of C-peptide
leads to activation of atypical PKCe. PKCe, together with another
atypical PKC isoform, PKCd, is involved in C-peptide-induced
stimulation of ERK1/2 [8]. Thus, the present paper provides
evidence to suggest that in HRTC, distinct pools and isoforms of
PKCs are independently involved in hyperglycemia- and C-
peptide-induced signaling.
Hyperglycemia activates the MAP kinase signaling pathway in
number of cell types and tissues [28]. In HRTC high glucose
concentrations stimulate total ERK1/2 phosphorylation C-
peptide stimulation. However, only a physiological concentration
of C-peptide promotes ERK nuclear accumulation and phosphor-
ylation independently from glycemic status. Taken together, our
findings provide evidence to suggest a pathway for chronic C-
peptide signaling via PKCe activation, ERK1/2 nuclear accumu-
lation and activation of nuclear transcription factors.
To explore the molecular mechanisms by which C-peptide and
glycemic status regulates kidney cell Na,K-ATPase isoform expres-
sion, we determined transcription factor activity by using a DNA-
binding assay. ZEB (AREB6) is expressed in multiple tissue/cell types
and has been identified as a specific transcription factor regulating the
Na,K-ATPase a1-subunit gene [25]. ZEB has a consensus sequence
located in the promoter of the rat and human a1-subunit gene [23].
In rats, ZEB DNA binding activity and a1-subunit mRNA and
protein expression was elevated after high-fat diet intervention,
preceding the development of hyperinsulinemea and insulin
resistance [35]. Despite these reported earlier correlative observa-
tions, the molecular mechanism regulating the genes encoding Na,K-
ATPase is incompletely understood. We found that C-peptide
increases ZEB DNA binding in HRTC, most profoundly in response
to C-peptide within physiological concentration range. Importantly,
this effect is independent from hyperglycemia. C-peptide-induced
increase in ZEB DNA binding and Na,K-ATPase a1-subunit
expression was abolished by PKC and MAP kinase inhibitors, which
is in agreement with data concerning C-peptide-induced specific
PKCe and ERK1/2 activation. Moreover, partial gene silencing of
ZEB markedly reduced effect of C-peptide on increase in Na,K-
ATPase a1-subunit expression. However, the direct effects of PKCe
and ERK1/2 on ZEB activation require further elucidation.
We have previously shown that C-peptide stimulates Na,K-
ATPase activity in HRTC acutely via translocation of a1- and b1-
subunits to the basolateral membrane from an endosomal
compartment by PKC- and ERK1/2 dependent mechanism
[12]. Here we provide evidence to show that physiological
concentrations of C-peptide stimulates sodium pump expression
via activation of ZEB, a transcription factor that has not been
previously implicated in C-peptide-mediated signaling. Our
findings suggest that despite activation of ERK1/2 and PKC by
hyperglycemia, distinct pools of PKCs and ERK1/2 are involved
in the regulation of Na,K-ATPase expression and activity by C-
peptide. Taken together, our findings suggest that PKCs and MAP
kinases are essential for C-peptide-stimulated Na,K-ATPase
activation (Fig. 6). These data support the growing body of
evidence for the involvement of ERK1/2 in acute and long term
Na,K-ATPase activation in different tissues.
Materials and Methods
Antibodies and reagents
Specific anti-a1-subunit monoclonal antibodies were obtained
from Dr. M. Caplan (Yale University, New Haven, CT). Rabbit
polyclonal anti-phospho PKC a/b, d, e and histone H3 were from
Cell Signaling Technology, Inc. (Beverly, MA) Monoclonal anti-
phospho-ERK1/2 (P-Thr
202/Tyr
204) and polyclonal anti-ERK1
were from New England BioLabs (Beverly, MA). Rabbit
antibodies raised against zinc finger/homeodomain protein
Figure 2. Culturing of HRTCs with 1 nM of C-peptide resulted
in increase in PKCe phosphorylation, while phosphorylation of
PKCs a/b increased by high glucose concentrations. Cells were
cultured as described in ‘‘Materials and Methods’’. Total cell lysates were
subject to Western blot analysis to determine PKCs phosphorylation. A
representative Western blot image is shown in the upper panel of each
graph. A. Phospho PKCa/b. B. Phospho PKCd, C. Phospho PKCe.
GAPDH protein was used as a loading control. Results are means 6 SE
for 6 independent experiments. * P,0.05 versus 5 mM glucose without
C-peptide.
doi:10.1371/journal.pone.0028294.g002
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Biotechnology (Santa Cruz, CA). Kinase inhibitors PD98059 and
GF109203X were from Calbiochem (La Jolla, CA). Cell culture
media and reagents were obtained from Invitrogen, Sweden.
Dimethylsulfoxide from Calbiochem was used as a solvent for
protein kinase inhibitors. All other reagents were of analytical
grade. Human recombinant C-peptide was obtained from
Schwarz Pharma (Monheim, Germany). Scrambled C-peptide
(the same amino acid residues as in C-peptide but in random
order) was from Sigma Genosys (Cambridge, UK). Horseradish
peroxidase-conjugated goat anti-rabbit and anti-mouse immuno-
globulin G was obtained from Bio-Rad Laboratories (Hercules,
CA). Reagents for enhanced chemiluminescence were obtained
from Amersham (Arlington Heights, IL). All other reagents were of
analytical grade (Sigma).
Cell culture
Human renal tubular cells (HRTC) were cultured from the
unaffected outer cortex of renal tissue obtained from non-diabetic
Figure 3. C-peptide in concentration of 1 nM stimulates ERK transocation into the nucleus and the kinase activatory
phosphorylation. Cells were cultured as described in ‘‘Materials and Methods’’. Total cell lysate and nuclear extracts were subject to Western
blot analysis to determine ERK1/2 abundance and phosphorylation. A representative Western blot image is shown in the upper panel of each graph.
A. The total ERK1 expression. B. ERK1 nuclear abundance . C. Total ERK1/2 phosphorylation. D. Nuclear ERK1/2 phosphorylation . GAPDH and histone
H3 proteins were used as loading controls for total cell lysate and nuclear extracts, respectively. Results are means 6 SE for 6 independent
experiments. * P,0.05 versus 5 mM glucose without C-peptide.
doi:10.1371/journal.pone.0028294.g003
Figure 4. C-peptide induced transcription factor ZEB DNA binding and Na,K-ATPase a1-subunit mRNA expression. A. Exposure to
1 nM of C-peptide increased DNA binding activity of ZEB detected by EMSA. B. The electrophoretic mobility supershift assay with specific antibodies
against ZEB. A–B. Experiments were performed at least 5 times and representative images are shown. C. mRNA expression of Na,K-ATPase a1-subunit.
Results are means 6 SE for 6 independent experiments. * P,0.05 versus 5 mM glucose without C-peptide.
doi:10.1371/journal.pone.0028294.g004
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Tissue collection was undertaken with the written informed consent
of the subject and approval by the Karolinska Institutet Ethics
Committee. The cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 5 mM gluco-
se,10 mM HEPES, bensylpenicillin (100 U/ml) and streptomycin
(100 mg/ml) and passaged at near confluence by trypsinization.
Growing cells exhibited epithelial morphology with a central
nucleus, a granular cytoplasm and cobblestone appearance on light
microscopy. Cells from the second and third passages were used for
experiments. Then cells were cultured for 5 days in 5 mM glucose
and 20 mM mannitol, or in 25 mM glucose in absence or presence
of 1 nM or 10 nM of C-peptide, as indicated. The cell culture
medium with all additions was replaced daily.
siRNA transfections in HRTC
HRTC cultured in 6-well plates were transfected using
Lipofectamine 2000 reagent (Invitrogen). The medium was
changed to antibiotic-free growth medium on day 1 of the HRTC
culture protocol. On day 2 HRTC were transfected with
individual siRNAs (1 mg/ml) using Lipofectamine 2000 in
serum-free RPMI 1640 media. The siRNA sequence GGU
AGA UGG UAA UGU AAU Att (Life Technologies) directed
against human ZEB or a scrambled sequence were used. Cells
were washed with PBS, and 2 ml of RPMI 1640 supplemented
with 10% fetal calf serum, 2 mM L-glutamine, 5 mM glucose,
10 mM HEPES was then added to each well. Then cells were
cultured for 5 days in 5 mM glucose and 20 mM mannitol, in
absence or presence of 1 nM of C-peptide.
Cell incubation
For total Na,K-ATPase and ERK1 expression and PKC
phosphorylation analysis, cells were washed twice with ice-cold
PBS, and harvested by scraping cells into ice-cold lysis buffer A
(20 mM Tris pH 8.0, 135 mM NaCl, 1 mM MgCl2, 2.7 mM KCl,
10 mM Na4P2O7, 0.5 mM Na3VO4, 10 mM NaF, 1 mM okadaic
acid, 1% Triton X-100, 10% v/v glycerol, 0.2 mM PMSF, 10 mg/ml
leupeptin, and 10 mg/ml aprotinin). Homogenates were rotated for
60 min at 4uC and subjected to centrifugation (12,0006g for 10 min
at 4uC). Protein concentration was determined using a bicinchoninic
acid protein assay kit (Pierce Chemical Co., Rockford, IL). Lysates





The transport activity of Na,K-ATPase was measured by
ouabain-sensitive
86Rb
+ uptake under conditions of initial rate, as
Figure 5. Na,K-ATPase expression regulates via PKC , ERK1/2
and ZEB activation. A. Cells were cultured, incubated with kinase
inhibitors and analyzed as described in ‘‘Materials and Methods’’.
Experiments were performed at least 5 times and representative
Western blot or EMSA images are shown. GAPDH protein was used as a
loading control for total cell lysate. B. Effect of siRNA- mediated
silencing of ZEB on ZEB and Na,K-ATPase a1-subunit protein expression
in HRTC. GAPDH protein was used as a loading control. Experiments
were performed at least 4 times and representative images are shown.
doi:10.1371/journal.pone.0028294.g005
Figure 6. Schematic representations of intracellular signaling
pathways for regulation of the sodium pump activity by C-
peptide in human renal tubular cells. C- peptide binds specifically
to a membrane structure, most likely a G-protein coupled receptor, with
subsequent activation of PLC, isoforms of both classic and novel PKC,
Rho A, MEK1/2 and ERK1/2. The latter elicits activation of ZEB (AREB6)
and regulation of the gene expression for Na,K-ATPase a1-subunit.
doi:10.1371/journal.pone.0028294.g006
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Cambridge, MA) in 5 mM glucose and 20 mM mannitol, or in
25 mM glucose in absence or presence of 1 nM or 10 nM of C-
peptide, as indicated. Before the measurement, cells were
preincubated in 950 ml serum-free RPMI 1640 without or with
ouabain (1 mM) for 15 min at 37uC. Thereafter the transport
activity of Na,K-ATPase was determined after the addition of
50 ml of medium containing tracer amounts of
86RbCl (100 nCi/
sample; Amersham, UK) for 15 min. Incubation was stopped by
cooling on ice and dishes were washed three times with an ice-cold
solution containing 150 mM choline-chloride, 1.2 mM MgSO4,
1.2 mM CaCl2, 2 mM BaCl2, and 5 mM HEPES, pH 7.4. Cells
were lysed in 750 ml lysis buffer A, and the radioactivity was
measured by liquid scintillation. Protein content was determined
in parallel by using the bicinchoninic acid assay (Pierce, Rockford,
IL). The ouabain-sensitive
86Rb
+ uptake was calculated as the
difference between the mean values measured in triplicate samples
incubated without or with 0.2 mM ouabain and was expressed as
% of control. Basal ouabain-sensitive
86Rb
+ uptake was 16.562.3
picomoles Rb
+ per microgram of protein per minute.
Preparation of basolateral membrane from HRTC
After treatment cells were washed twice with ice-cold PBS, and
harvested by scraping cells into 500 ml of ice-cold buffer (12 mM
HEPES, 300 mM mannitol, pH 7.6 (Tris 1 M), 0.5 mM Na3VO4,
0.2 mM PMSF, 5 mg/ml leupeptin, 5 mg/ml aprotinin and 1 mM
microcystin). Cells were homogenized by Pellet Pestle twice for
1 min, and passing through insulin syringe with 21G needle 10–12
times into an Eppendorf tube. Homogenates were pre-cleaned
by centrifugation at 2,5006g for 15 min. Supernatants were
collected. Pellets were resuspended in 500 ml of homogenization
buffer, and spun down at 2,5006g for 15 min. Supernatants were
collected and transferred to the tubes, containing the first 500 ml,
and centrifuged at 20,0006g for 20 min, +4u C on TLA 100.2
Beckman rotor. Basolateral membranes (BLM) were further
purified [12], using a Percoll gradient. The yellow layer of pellet
was resuspended again in the supernatant (carefully removed from
the brown pellet containing mitochondria and cell ghosts) and
centrifuged at 48,0006g for 30 min. The supernatant was
discarded, and the pellet was resuspended in 1 ml of buffer
(300 mM mannitol and 12 mM HEPES, pH 7.6, adjusted with
Tris) by gentle pipetting. To form a Percoll gradient, 0.19 g of
undiluted Percoll (Pharmacia Biotech Inc.) was added to a 1-ml
suspension (0.8–1.0 mg of protein). The suspension was gently
mixed and centrifuged at 48,0006g for 30 min, and the ring of
BLM, light endosomal fraction (the top 1/3 part of the tube), and
pellets were collected and frozen at 220uC. Protein content was
determined by using the bicinchoninic acid assay (Pierce).
Determination of Na,K-ATPase activity
Na,K-ATPase activity was measured at maximum velocity
(Vmax) conditions in BLM fractions, essentially as described [36].
Aliquots of BLM fractions (protein content, 2–3 mg) were
transferred to the Na,K-ATPase assay medium (final volume
100 ml), containing 50 mM NaCl, 5 mm KCl, 10 mM MgCl2,
1 mM EGTA, 50 mm Tris-HCl, 10 mM Na2ATP, and c-
32P-
ATP (NEN Life Science Products; specific activity, 3000 Ci/
mmol) in tracer amounts (3.3 nCi/ml), at 4uC. The samples were
then incubated at 37uC for 15 min. The reaction was terminated
by rapid cooling to 4uC and addition of a mixture of
trichloroacetic acid/charcoal (5%/10%). After separating the
charcoal phase (12,0006g for 5 min) containing the nonhydro-
lyzed nucleotide, the
32Pi liberated in the supernatant was
counted. Na,K-ATPase activity was calculated as the difference
between test samples (total ATPase activity) and samples assayed
in a medium devoid of Na
+ and K
+ and in the presence of 2 mM
ouabain (ouabain-insensitive ATPase activity). Protein determina-
tion was performed as described above.
Nuclear extraction
The nuclear extraction procedure was essentially as described
previously [37], with some modifications. Cells were grown in 10-
cm Petri dishes, at the last day of the experiment were incubated
overnight with 20 mM PD98059 (MEK1 inhibitor), 1 mMo r
10 mM GF109203X (PKC inhibitor), as indicated and then
washed with ice-cold PBS. Cells were scraped in 600 ml of PBS
and transferred to microcentrifuge tubes. After centrifugation at
350 g for 30 s, cells were resuspended in 300 ml of buffer [10 mM
HEPES-KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), and 0.2 mM phenylmethylsulfonyl fluoride
(PMSF)]. Cells were left to swell for 15 min. After centrifugation,
the pellet, which contains the nuclear proteins, was resuspended
with 20 ml of buffer (20 mM HEPES-KOH, pH 7.9, 1.5 mM
MgCl2, 420 mM NaCl, 25% glycerol, 0.2 mM EDTA, 0.5 mM
DTT, and 0.2 mM PMSF). The nuclear proteins were left to
diffuse into the buffer for 30 min. The supernatant, with the
nuclear proteins, was collected in microcentrifuge tubes supple-
mented with 50 ml of low-saline buffer (10 mM HEPES-KOH,
pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, and 0.2 mM PMSF).
Protein concentration of the resulting supernatant was determined
using a bicinchoninic acid assay (Pierce).
Electrophoretic mobility shift assay
ZEB DNA binding activity was determined by an electrophoretic
gel mobility shift assay (EMSA) as described previously [34].
Oligonucleotides for the consensus binding sites for zinc finger/
homeodomain protein (ZEB) transcription factor were purchased
from Santa Cruz Biotechnology (Santa Cruz,CA). Oligonucleotides
were end-labeled with T4 polynucleotide kinase (Santa Cruz) and
2 mCi of [c-
32P]ATP. Nuclear extracts (1.5–2.5 mg) were incubated
for 20 min in reaction mixture containing 2 mg poly(dI-dC),
0.5 mM DTT, 25 mM Tris-HEPES, pH 7.5, 60 mM KCl,
1 mM EDTA, and 12% glycerol (15 min on ice and 5 min at
room temperature). As a negative control, unlabeled competitor
oligonucleotide was incubated with stimulated cell nuclear extract
before the addition of labeled probe.
32P-labeled probes (0.5 ng)
were incubated with the protein-mixture complex for 30 min at
room temperature. Thereafter, 20 ml aliquots were loaded on a
nondenaturing 5% polyacrylamide (30% acrylamide/bisacryla-
mide) gel buffered with Tris-borate-EDTA (10 mM Tris, 90 mM
boric acid, 1 mM EDTA) and subjected to electrophoresis at
40 mAfor1.5 hatroomtemperature.Thedriedgelswereanalyzed
using a phosphoimager (Fuji model BAS-1800II). For supershift
analysis of ZEB, nuclear extracts were incubated for 1 h with ZEB
antibodies (Santa Cruz). To exclude nonspecific binding, extracts
were incubated with unlabeled ZEB oligo. The mixture was then
incubated with radioactively labeled oligo for 30 min at room
temperature. Samples were loaded as described above.
Real time PCR
Quantification of the mRNA expression of Na,K-ATPase a1-
subunits from HRTC was performed using quantitative real-time
PCR with the ABI PRISM 7000 Sequence Detector System and
fluorescence-based SYBR Green technology (Applied Biosystems,-
Warrington, UK). Total RNA was prepared from the tissue
samples using TRIzol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Synthesis of cDNA
was performed with random hexamer primers using SuperScript
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reactions contained 400 nm of each PCR primer and 16SYBR
Green PCR Master Mix (Applied Biosystems). The forward (F)
and reverse (R) primer sequences were as follows: for Atp1a1
(GenBank NM000707.7) GGCTGTCATCTTCCTCATTGG (F)
and CGGTGGCCAGCAAACC (R). All samples were run in
duplicate, and the relative quantities of different mRNA
transcripts were calculated after normalization of the data against
18S, as endogenous controls, using relative quantification method.
Western blot analysis
Aliquots of cell lysates (30 mg of protein) and fractions of
basolateral membranes (10 mg of protein) were resuspended in
Laemmli sample buffer. Proteins were then separated by SDS/
PAGE, transferred to PVDF membranes, blocked with 7.5% non-
fat milk, washed with TBST (10 mM Tris HCl, 100 mM NaCl,
0.02% Tween 20) and incubated with appropriate antibodies
overnight at 4uC. Membranes were washed with TBST and
incubated with an appropriate secondary antibody. Proteins were
visualized by enhanced chemiluminescence and quantified by
densitometry.
Statistics
Data are presented as mean 6 SE. Comparisons between
groups were performed using Student’s t-test. For multiple
comparisons, one-way ANOVA with Scheffe’s correction was
used. Significance was established at P,0.05.
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